Technosphere Insulin
Asset
Inhaled rapid-acting human insulin formulation that activates the insulin receptor.
- Stage
- Phase 2
- Modality
- Protein or enzyme
- Target
- Insulin/IGF-1 signalling
- 2
- Indications
- 212
- Trials
- 1
- Developer
Indications
2Type 2 diabetes
Phase 2, Completed, NCT00419302, clinicaltrials.gov, 7 Oct 2026
Chronic obstructive pulmonary disease
Phase 1, Completed, NCT01021891, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains4
- Owner and partners1
- Trials212
- Evidence for its targets4
- Competitors12
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.